Postpartum Thyroiditis: What the New 2026 ATA Guidelines Say About Selenium, Monitoring, and the Natural Course

This article is for educational purposes intended for healthcare practitioners and informed readers. It does not constitute medical advice.

Why This Guideline Update Matters

In June 2026, the American Thyroid Association published its first full revision of thyroid-in-pregnancy guidance since 2017: the "American Thyroid Association 2026 Guidelines for Thyroid Disease in Preconception, Pregnancy, and Postpartum," led by Korevaar, Leung, and a multidisciplinary international writing group, published in Thyroid. Among the updates is a specific, graded recommendation that runs against a protocol many naturopathic and integrative practitioners still reach for by default: routine selenium supplementation to prevent or treat postpartum thyroiditis (PPT). The guideline states plainly that for euthyroid women positive for thyroid peroxidase or thyroglobulin antibodies (TPOAb and/or TgAb), clinicians should "not offer selenium supplementation," a conditional recommendation rated on moderate-quality evidence, and separately states in its postpartum thyroiditis section that the writing group does "not advise routine selenium supplementation for the prevention of PPT."

That is worth sitting with, because selenium is one of the best-evidenced single nutrients in autoimmune thyroid care generally. Our Hashimoto's thyroiditis guide covers the genuinely strong randomized-trial base for selenium reducing anti-TPO antibody titres outside pregnancy, and selenium also has real trial support for a completely different indication, mild Graves' orbitopathy, discussed in our Graves' disease evidence review. The pregnancy and postpartum picture is a distinct evidence base with a different outcome, and it does not support the same confidence. This article walks through why, what actually happened across the key trials, and what the new guideline recommends instead.

What Postpartum Thyroiditis Actually Is

PPT is defined in the 2026 guideline as a pattern of transient autoimmune thyroid dysfunction occurring within twelve months after delivery (it can also follow a pregnancy loss). The guideline estimates prevalence at roughly 8%, based mainly on observational cohorts, and notes that because most studies have focused on clinically apparent disease, a substantial share of PPT is likely never identified. The classic course is triphasic: destructive thyrotoxicosis from the release of preformed hormone out of an inflamed gland, typically starting one to six months postpartum, followed in some women by a hypothyroid phase around four to eight months postpartum, then gradual return to euthyroidism over two to three more months. Not everyone follows the full pattern. The guideline's own breakdown of PPT subtypes is: destructive thyroiditis alone (about 50% of cases), biphasic destructive thyroiditis (about 20%), transient hypothyroidism alone (about 25%), and permanent hypothyroidism (about 5%) from the outset.

The single strongest risk factor is TPOAb positivity assessed in the first trimester. Women with a documented history of PPT face a 70% risk of recurrence in a future pregnancy, and even among women whose thyroid function initially normalizes after an episode, 10 to 50% go on to develop permanent hypothyroidism later in life, a figure echoed in a 2011 prospective cohort from southern Italy that found 54% of 169 women with PPT had persistent hypothyroidism by the end of the first postpartum year. Other factors associated with progression to permanent hypothyroidism include multiparity, thyroid hypoechogenicity on ultrasound, greater severity of the initial hypothyroid phase, and older maternal age.

Why Selenium Looked Promising: The Early Trial

The case for selenium in PPT rests substantially on a single trial published in 2007: Negro and colleagues randomized euthyroid, TPOAb-positive pregnant women to selenomethionine or placebo and reported a reduction in postpartum thyroid dysfunction and antibody titres in the treated group, a genuinely encouraging result that shaped a decade of clinical practice recommendations, including in many naturopathic and functional medicine protocols for Hashimoto's-pattern thyroid disease identified during pregnancy.

Why the Evidence Did Not Hold Up

Two more recent, larger, and more methodologically rigorous trials complicate that picture considerably.

A 2016 randomized trial by Mao, Pop, Bath, and colleagues in UK pregnant women with mild-to-moderate iodine deficiency tested low-dose selenium specifically against thyroid autoimmunity and thyroid function outcomes. The 2026 ATA guideline cites this trial, alongside Negro's, as part of the "mixed results" body of evidence, and notes specifically that the available selenium trials are mostly small cohorts conducted in parts of Europe where background selenium nutrition may itself be marginal, a detail that limits how far any positive finding generalizes to populations with adequate baseline selenium status.

The more directly comparable and more recent trial is the SERENA study, published by Mantovani, Isidori, Moretti, and colleagues in Endocrine in 2019. This was a multicentre, randomized, double-blind, placebo-controlled trial conducted across ten endocrine and obstetric centres in Italy, enrolling 45 TPOAb-positive pregnant women between 4 and 8 weeks' gestation, randomized to oral L-selenomethionine 83 mcg/day or placebo, continued until six months after delivery. TPO antibody levels fell in both groups during pregnancy, as is commonly seen regardless of treatment, but after delivery they continued falling in the selenium group while rising again in the placebo group, a real and statistically meaningful antibody effect. The problem is what did not move: thyroid function, thyroid volume and ultrasound appearance, and health-related quality of life showed no differences between groups at any point, and the trial's own authors describe this as supporting the ATA's recommendation against routine selenium supplementation in pregnancy. In other words, selenium measurably dampened the antibody rebound without producing a detectable clinical benefit in the outcome that actually matters to a patient: whether she develops postpartum thyroid dysfunction.

This is precisely the distinction the 2026 guideline draws. Reducing an antibody titre is a biomarker effect, not necessarily a patient-relevant one, and across the accumulated trial base, selenium has not reliably translated into fewer cases of postpartum thyroiditis, less severe disease, or better quality of life. That is a materially different, and weaker, evidence profile than the non-pregnant Hashimoto's literature covered in our Hashimoto's guide, where trials by Gärtner, Duntas, and Mazokopakis using the same 200 mcg/day selenomethionine dose outside pregnancy showed consistent reductions in anti-TPO titres alongside a stronger overall signal. Selenium for Graves' orbitopathy, by contrast, is an entirely separate indication with its own positive randomized trial evidence and should not be confused with either of these.

What the 2026 Guideline Recommends Instead

Rather than a selenium protocol, the ATA's postpartum thyroiditis recommendations centre on education, symptom-triggered treatment, and structured long-term follow-up:

• TPOAb-positive women, or those with a prior history of PPT, should be counselled about the high recurrence risk and the symptoms that warrant thyroid function testing (a conditional recommendation on low-quality evidence, reflecting an emphasis on shared decision-making rather than a hard screening mandate).
• During the thyrotoxic phase, women with hyperthyroid symptoms should be treated with the lowest effective dose of a beta-blocker; propranolol or metoprolol can be used during lactation. Antithyroid drugs are not indicated in this phase, because the thyrotoxicosis is destructive rather than driven by excess hormone synthesis, unlike Graves' disease.
• During the hypothyroid phase, levothyroxine may be considered if the woman is symptomatic, breastfeeding, or planning another pregnancy within six months, with a planned taper to assess recovery after six to twelve months rather than indefinite treatment by default.
• Once thyroid function tests normalize after an episode, retesting should occur at one year postpartum, or sooner if hypothyroid symptoms develop, given the meaningful long-term risk of permanent hypothyroidism described above.

The guideline explicitly states that levothyroxine given to TPOAb-positive pregnant women earlier in gestation does not change the course of PPT and is not recommended as a preventive strategy either, placing it in the same position as selenium: a plausible-sounding prevention strategy that has not been borne out as effective once properly tested.

Distinguishing Postpartum Thyroiditis From a Graves' Flare

Because both can present with postpartum thyrotoxicosis, getting the diagnosis right changes management substantially; our Graves' disease and hyperthyroidism review covers autoimmune hyperthyroidism in more general detail. The 2026 guideline notes that the thyrotoxic phase of PPT typically begins one to six months postpartum and resolves within three months, with TRAb and TSI negative, whereas Graves' disease more often presents three to twelve months after delivery, persists longer, and is TRAb or TSI positive in most cases. A total triiodothyronine to total thyroxine ratio above 20 and increased thyroid vascularity on ultrasound favour Graves' disease; a ratio below 20 and low thyroid vascularity favour PPT. Where the picture is unclear, the guideline notes a radioactive iodine uptake scan can help, though this requires a temporary pause in breastfeeding.

Practical Implications for Naturopathic Practice

The honest summary is that selenium remains a reasonable, evidence-supported intervention for Hashimoto's thyroiditis outside pregnancy, and a separately evidenced intervention for mild Graves' orbitopathy, but it is not currently supported as a routine preventive or treatment strategy specifically for postpartum thyroiditis, despite an encouraging early signal from a single 2007 trial that did not replicate in the clinically relevant outcomes of later, more rigorous studies. A patient identified as TPOAb-positive during pregnancy, or with a personal history of PPT, is better served by the ATA's actual recommended pathway: education about the roughly 70% recurrence risk in a future pregnancy, scheduled thyroid function testing through the postpartum year, symptom-triggered beta-blockade for a thyrotoxic phase, and a time-limited trial of levothyroxine for a symptomatic hypothyroid phase rather than a selenium protocol presented as prevention. Given the real long-term risk of permanent hypothyroidism after PPT (10 to 50% in longitudinal studies), the one-year follow-up testing recommendation is the single highest-value piece of this guideline for naturopathic practitioners to actually implement and track, because it is the step most likely to be missed once a patient's acute symptoms have resolved.

When to Refer or Escalate

Significant thyrotoxic symptoms (marked tachycardia, arrhythmia, severe anxiety or tremor) in the postpartum period warrant prompt medical evaluation to rule out a Graves' flare, which carries different treatment implications, including possible antithyroid drug therapy. Any woman with a prior PPT episode who is planning another pregnancy should have her thyroid status checked and discussed with her treating clinician beforehand given the high recurrence risk. Significant depressive symptoms in the postpartum period should prompt thyroid function testing per standard practice, though the guideline notes the evidence does not support a direct causal link between PPT specifically and postpartum depression risk, so a depression presentation should not be assumed to be thyroid-driven without testing to confirm it.

Clinical Summary

The 2026 American Thyroid Association guideline on thyroid disease in preconception, pregnancy, and postpartum explicitly recommends against routine selenium supplementation for euthyroid, thyroid-antibody-positive pregnant women, and separately advises against selenium as a postpartum thyroiditis prevention strategy, reversing what an encouraging 2007 trial by Negro and colleagues had suggested. The more rigorous SERENA trial (2019) and a 2016 UK trial found that selenium can suppress the postpartum rebound in TPO antibody titres without producing any measurable improvement in thyroid function, thyroid ultrasound findings, or quality of life, the outcomes that actually matter clinically. This is a materially different evidence picture from selenium's use in Hashimoto's thyroiditis outside pregnancy or in mild Graves' orbitopathy, where the trial evidence is stronger, and the distinction should be made explicitly to patients rather than treating "selenium helps autoimmune thyroid disease" as a single, context-free claim. The guideline's own recommended approach centres on patient education about recurrence risk, symptom-triggered beta-blockade or levothyroxine by phase, and thyroid function retesting at one year postpartum given the substantial risk of permanent hypothyroidism after an episode.

References

• Korevaar TIM, Leung AM, Alexander EK, et al. "American Thyroid Association 2026 Guidelines for Thyroid Disease in Preconception, Pregnancy, and Postpartum." Thyroid. 2026;36(5):481-544. DOI: 10.1177/10507256261445624. Open-access full text: eScholarship.
• Mantovani G, Isidori AM, Moretti C, Di Dato C, Greco E, Ciolli P, Bonomi M, Petrone L, Fumarola A, Campagna G, Vannucchi G, Di Sante S, Pozza C, Faggiano A, Lenzi A, Giannetta E. "Selenium supplementation in the management of thyroid autoimmunity during pregnancy: results of the 'SERENA study', a randomized, double-blind, placebo-controlled trial." Endocrine. 2019;66(3):542-550. DOI: 10.1007/s12020-019-01958-1. PMID: 31129812.
• Negro R, Greco G, Mangieri T, Pezzarossa A, Dazzi D, Hassan H. "The influence of selenium supplementation on postpartum thyroid status in pregnant women with thyroid peroxidase autoantibodies." Journal of Clinical Endocrinology & Metabolism. 2007;92(4):1263-1268. DOI: 10.1210/jc.2006-1821. PMID: 17284630.
• Mao J, Pop VJ, Bath SC, Vader HL, Redman CWG, Rayman MP. "Effect of low-dose selenium on thyroid autoimmunity and thyroid function in UK pregnant women with mild-to-moderate iodine deficiency." European Journal of Nutrition. 2016;55(1):55-61. DOI: 10.1007/s00394-014-0822-9.
• Stagnaro-Green A, Schwartz A, Gismondi R, Tinelli A, Mangieri T, Negro R. "High rate of persistent hypothyroidism in a large-scale prospective study of postpartum thyroiditis in southern Italy." Journal of Clinical Endocrinology & Metabolism. 2011;96(3):652-657. DOI: 10.1210/jc.2010-1980. PMID: 21190974.

This article is intended for educational purposes and professional practice reference. It does not constitute individual medical advice. Any postpartum thyroid symptoms, or a history of postpartum thyroiditis in a patient planning another pregnancy, should be assessed by a qualified healthcare provider.